Escobedo MF, García-Consuegra L, Gay S, Álvarez L, Olay S, Ascani G, Junquera L. Influence of the teaching program on the learning in knowledge and practice of osteonecrosis of the jaws produced by antireasorptives in dental students of the Principality of Asturias (Spain). J Clin Exp Dent. 2017;9(12):e1402-7.

 

doi:10.4317/jced.54129

http://dx.doi.org/doi:10.4317/jced.54129

 

References

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7.
https://doi.org/10.1016/S0278-2391(03)00720-1

PMid:12966493

 

2. Gavaldá C, Bagan JV. Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature. Med Oral Patol Oral Cir Bucal. 2016;21:260-70.
https://doi.org/10.4317/medoral.21001
PMCid:PMC4867198

 

3. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, Silvestre FJ, Scully CJ. Oral Pathol Med. 2005;34:120-3.
https://doi.org/10.1111/j.1600-0714.2004.00269.x
PMid:15641993

 

4. Sammut S, Malden N, Lopes V, Ralston S. Epidemiological study of alendronate-related osteonecrosis of the jaw in the southeast of Scotland. Br J Oral Maxillofac Surg. 2016;54:501-5.
https://doi.org/10.1016/j.bjoms.2015.10.036
PMid:26975575

 

5. Khan A, Morrison A, Cheung A, Hashem W, Compston J. Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int. 2016;27:853-9.
https://doi.org/10.1007/s00198-015-3335-3
PMid:26493811

 

6. Black D, Delmas P, Eastell R, et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. The New England Journal of Medicine. 2007;18:1809-22.
https://doi.org/10.1056/NEJMoa067312
PMid:17476007

 

7. Katz J, Ordoveza PA. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) associated with a once-yearly IV infusion of zoledronic acid (Reclast) 5 mg: two cases and review of the literature. Quintessence Int. 2014;45:685-90.
PMid:25019116

 

8. Lee CY, Suzuki JB. Medication-related osteonecrosis of the jaws from once per year intravenous zoledronic acid (Reclast): report of 4 cases. Implant Dent. 2015;24:227-31.
https://doi.org/10.1097/ID.0000000000000227

PMid:25734948

 

9. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg. 2014;72:1938-56.
https://doi.org/10.1016/j.joms.2014.04.031
PMid:25234529

 

10. Alhussain A, Peel S, Dempster L, Clokie C, Azarpazhooh A. Knowledge, practices, and opinions of Ontario dentists when treating patients receiving bisphosphonates. J Oral Maxillofac Surg. 2015;73:1095-105.
https://doi.org/10.1016/j.joms.2014.12.040
PMid:25843818

 

11. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws–2009 update. J Oral Maxillofac Surg. 2009;67:2-12.
PMid:19371809

 

12. López-Jornet P, Camacho-Alonso F, Molina-Mi-ano F, Gomez-Garcia F. Bisphosphonate-associated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: a preliminary study. J Eval Clin Pract. 2010;16:878-82.
https://doi.org/10.1111/j.1365-2753.2009.01203.x
PMid:20663005

 

13. de Lima PB, Brasil VL, de Castro JF, de Moraes Ramos-Perez FM, Alves FA, dos Anjos Pontual ML, da Cruz Perez DE. Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw. Support Care Cancer. 2015;23:3421-6.
https://doi.org/10.1007/s00520-015-2689-6
PMid:25757408